B
BlueWillow Biologics
BlueWillow Biologics is a privately-held biopharmaceutical company
About BlueWillow Biologics
BlueWillow Biologics is a clinical-stage biotechnology company specializing in the development of intranasal vaccines and immunotherapies. The company operates in the biotechnology and healthcare markets, focusing on creating vaccines that can be administered through the nasal route. BlueWillow's proprietary oil-in-water emulsion adjuvant technology enhances the immune response by delivering antigens directly to the mucosal surfaces, which are the body's first line of defense against pathogens. This technology has shown compatibility with a broad range of antigens, making it versatile for various vaccine candidates. The company primarily serves healthcare providers, research institutions, and government agencies involved in public health and biodefense. BlueWillow's business model revolves around the development and licensing of its vaccine platform, as well as partnerships for clinical trials and commercialization. Revenue is generated through licensing agreements, research grants, and potential future sales of approved vaccines. The company has demonstrated human safety in over 400 clinical trial participants and continues to advance its pipeline of intranasal vaccines.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 21
- Open positions
- None listed
- Dealroom signal
- 28.0/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based
- Technology
- Deep Tech, Nanotech
- Business model
- Manufacturing
- Client focus
- B2B
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANTOther financing | Sep 2018 | — | — | Small Business Innovation Research | — |
| EARLY VCOther financing | May 2018 | $10M | $40M | North Coast Technology Investors | — |
Growth signals
Latest recorded traffic for BlueWillow Biologics is 1.9K monthly website visits, down 9.5% over the last three months. BlueWillow Biologics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
BlueWillow Biologics in the Ann Arbor ecosystem
The BlueWillow Biologics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed3 investors entered at this stage
Bill & Melinda Gates Foundation
US National Institute of Allergy and Infectious Diseases
Small Business Innovation Research
Series A3 investors entered at this stage
Perseus
Venture Investors Health Fund- NINorth Coast Technology Investors
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about BlueWillow Biologics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See BlueWillow Biologics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.








